Cybin announces grant of two new united states patents protecting its deuterated dmt program

Toronto--(business wire)--cybin inc. (nyse american:cybn) (neo:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced that the united states patent and trademark office has issued two patent grants that offer protection for its deuterated n, n-dimethyltryptamine (“dmt”) program. the granted patents protecting the company's deuterated dmt prog.
CYBN Ratings Summary
CYBN Quant Ranking